Supported Research

Search by keyword:

Full Archive

EXTENDED FUNDING: Fanconi Anemia Cancer Translational Resource

2020 | | Raymond Monnat, Jr.

Fanconi anemia (FA) patients are at exceptionally high risk of developing epithelial cancers. We aim to identify features of these cancers that provide new insight into their origins, and better ways to treat these cancers in the context of FA patients. As part of this Resource we will develop and c…

NEW: A small molecule approach to overcome replication dysfunction in FA

2020 | Research Grant | Sharon Cantor, Peter Kurre

The goal of this project is to identify drugs that improve DNA integrity and bone marrow stem cell function in FA. The Cantor lab has uncovered defects in so-called DNA replication that lead to small gaps and compromise cell turnover and fitness of FA cells. Striking similarities with the data gener…

NEW: Correction of Fanconi Anemia Mutations using Digital Genome Engineering

2020 | Research Grant | Branden Moriarity, John Wagner, Beau Webber

While the transplantation of healthy blood-forming stem cells from a healthy related or unrelated donor is the current standard of care for FA patients, this treatment carries a significant risk of morbidity and mortality caused by the toxic preconditioning regimen and immunological complications. O…

NEW: Pathogenesis, clinical and treatment outcomes, and molecular characteristics of anogenital squamous cell carcinomas in individuals with Fanconi Anemia

2020 | Research Grant | Kathryn Pennington, Agata Smogorzewska

Individuals with FA have an increased risk of developing anogenital squamous cell carcinoma (cancer of the vulva, cervix, vagina, or anus), but the best and safest way to treat these cancers in individuals with FA is unknown because only a small numbers of cases have been published in the medical li…

NEW: Reducing the burden of squamous cell carcinoma in Fanconi anemia (2020)

2020 | Service Grant | Christine Krieg, Eunike Velleuer

As individuals with FA reach adulthood, they have an increased risk of developing cancer, especially head and neck and anogenital squamous cell carcinoma. Cancer treatment options for individuals with FA are limited due to the DNA repair defects associated with the disease. Therefore, there is an ur…

NEW: Synthetic Lethal Approaches to Treatment of FA Gene Mutant Head and Neck Cancer

2020 | Research Grant | Barbara Burtness, Gary Kupfer

Head and neck cancer in adult Fanconi anemia patients is often poorly managed with standard treatments. New drugs that work on controlling the cell cycle and cell division, rather than by damaging the cell’s DNA, may be safer in patients with FA. Researchers have preliminary evidence that combinatio…

A Porcine Model of Fanconi Anemia (2019)

2019 | Research Grant | William Fleming, Markus Grompe

A limitation in FA research is the absence of a live model that displays key features of the disease. Researchers at OHSU will create the first large animal model of FA to test potential therapies for people with FA.

Complete DNA sequencing of the Fanconi anemia patient tumors

2019 | Research Grant | Agata Smogorzewska

Fanconi anemia patients have a very high predisposition to head, neck, and anogenital squamous cell carcinoma (SCC). To understand how these cancers develop, Dr. Smogorzewska and team are cataloging genetic changes that are present in the cancers. They are using the latest DNA sequencing technologie…

CRISPR transcriptional screens for re-activation of HDR in FA patient-derived cells

2019 | Research Grant | Jacob Corn

There is a great deal of excitement about the potential of CRISPR genome editing to treat disorders such as Fanconi anemia. But the mutations that cause FA also reduce the effectiveness of genome editing. Dr. Corn and colleagues will search for potential ways to re-activate genome editing in FA pati…

Gefitinib/Afatinib therapy for Head and Neck Squamous Cell Carcinomas in Fanconi anemia

2019 | Research Grant | Jordi Minguillón, Jordi Surralles

Beyond surgical resection, there is no effective therapy nowadays to treat FA patients that develop solid tumors, so a drug able to kill tumor cells but nontoxic for FA patients is of critical relevance. Gefitinib and afatinib candidates are approved drugs and are already being used in cancer therap…

High-priority agents for Fanconi anemia-associated oral cancer treatment and prevention

2019 | Research Grant | Frank G. Ondrey

Oral cancer in Fanconi patients is a severe disease requiring innovative treatment and prevention measures. The potential use of FDA-approved diabetes drugs is a practical strategy for Fanconi patients for oral cancer prevention or treatment studies, once these preliminary studies are conducted. The…

Metabolic alterations in glucose utilization and carnitine biosynthesis impact nutritional status in individuals with FA

2019 | Research Grant | Adam Nelson, Lindsey Romick-Rosendale

Persons with FA, as well as their family members, voice concern about being underweight and unable to build muscle mass. These concerns have an obvious physical impact, not only on the person's appearance to others and themselves and the negative impact on immune function and host defense but also h…